2019 Pharma Companies to Watch Report
Robert Flynn and Ken Sawka
This proprietary qualitative analysis identifies five top pharmaceutical companies that stand out as major disruptors. Fuld + Company’s analysis includes […]
Premdharan (Prem) Meyyan serves as Associate Director with Fuld + Company’s Health + Life Science Practice and has robust background across multiple biotechnology disciplines across a number of indications with special interest in clinical-stage pharma and medtech. Prem has a passion for new technology and staying abreast of broader industry trends. His market and competitive analyses have been featured in various publications including Yahoo Finance, Diagnostic & Interventional Cardiology, PM360, Medical Design Technology, Clinical Leader, and others.